PET/CT and scintigraphy scans were resumed in our Department of Nuclear Medicine in mid-January 2023, following the realisation of a service procurement tender, with a new PET/CT device and a double detector gamma camera brought by the contractor company, after all scans were suspended for a period of time after the obsolete gamma camera SPECT and PET/CT devices became unusable. Within the scope of this service procurement tender, the contractor company made all the modifications and fabrications required by the Nuclear Regulatory Authority in the infrastructure of the department. In addition, all radioactive and pharmaceutical materials and equipment used in imaging are provided by the contractor company in an uninterrupted and complete manner and the continuity of the service is ensured.
Study Subjects and Service Areas
In addition to scintigraphic examinations with a double detector gamma camera (GE DISCOVERY NM630), 18-F FDG and Ga-68 neuropeptide and Ga-68 PSMA studies are performed with a PET/CT device (GE DISCOVERY IQ).
DIAGNOSTIC NUCLEAR MEDICINE APPLICATIONS :
Nuclear Oncology
- Nuclear Oncology
- Ga68-PSMA PET/CT
- Tumour imaging with Ga68-DOTATATE
Skeletal System
- Three-phase regional bone scintigraphy
- Whole body bone scintigraphy
- Bone SPECT
Endocrine System
- Thyroid scintigraphy
- Parathyroid scintigraphy (with Tc-99m MIBI)
- Ga68- DOTATATE PET/CT study
Respiratory System
- Lung perfusion scintigraphy
Central Nervous System
- Brain perfusion SPECT
- BRAIN F18 FDG PET/CT
Genitourinary System
- Renal scintigraphy (with or without diuretic) with Tc-99m MAG 3
- Renal cortical scintigraphy (Tc-99m DMSA)
- Captopril renogram (double study)
Cardiovascular System
- Myocardial perfusion scintigraphy (SPECT) with Tc-99m complexes
- Myocardial perfusion GATED SPECT with Tc-99m complexes
NUCLEAR MEDICINE APPLICATIONS IN TREATMENT
- Y-90 Hepatic transarterial radionuclide therapy (TARE) with microsphere
